NGL FINECHEM
Back to Balance Sheet
|
NGL FINECHEM Last 5 Year Total Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Total Liabilities | ₹560 Cr | ₹442 Cr | ₹356 Cr | ₹287 Cr | ₹277 Cr |
What is the latest Total Liabilities ratio of NGL FINECHEM ?
| Year | Total Liabilities |
|---|---|
| Mar2026 | ₹560 Cr |
| Mar2025 | ₹442 Cr |
| Mar2024 | ₹356 Cr |
| Mar2023 | ₹287 Cr |
| Mar2022 | ₹277 Cr |
How is Total Liabilities of NGL FINECHEM Trending?
| Years | Total Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹560 Cr | 26.83 | |
| Mar2025 | ₹442 Cr | 24.29 | |
| Mar2024 | ₹356 Cr | 23.85 | |
| Mar2023 | ₹287 Cr | 3.67 | |
| Mar2022 | ₹277 Cr | - | |
Compare Total Liabilities of peers of NGL FINECHEM
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NGL FINECHEM | ₹2,129.8 Cr | 5.2% | 6.8% | 182.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹466,431.0 Cr | -2.3% | 3% | 12.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹220,115.0 Cr | 2.9% | 22.7% | 25.5% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹188,853.0 Cr | -2.7% | 2% | 33.9% | Stock Analytics | |
| CIPLA | ₹119,158.0 Cr | 0.1% | 3% | -7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹98,074.4 Cr | 2.4% | -12.9% | -9.1% | Stock Analytics | |
NGL FINECHEM Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NGL FINECHEM | 5.2% |
6.8% |
182.9% |
| SENSEX | 1.3% |
1% |
-2.9% |
You may also like the below Video Courses